tect BNP from degradation at room temperature and that BNP assays can be safely performed within the 8 h after sampling, with whole blood being preferably kept at 4°C, with all 3 instruments tested. 
Use of B-Type Natriuretic Peptide Testing in a Community Teaching Hospital 4 Years After Implementation and Agreement of Results with Discharge Diagnoses

To the Editor:
We previously reported on the use of B-type natriuretic peptide (BNP) testing in the 400-bed Hennepin County Medical Center at the inception of testing in August 2001 (1 ) . We now describe its use and report the agreement of the results with diagnoses in the patient records in this urban teaching hospital 4 years later.
We queried all BNP orders for June through August 2005 and found 975 test orders on 608 patients. To determine a diagnosis of heart failure, physician discharge dictations and ICD-9 codings were reviewed after Institutional Review Board approval. Final diagnoses were likely influenced by the BNP concentrations in some cases, potentially leading to overestimation of apparent diagnostic accuracy.
The Biosite Triage and Beckman Coulter Access BNP assays were performed according to the manufacturers' guidelines and were highly correlated (r ϭ 0.99; n ϭ 50), with Bland-Altman analysis demonstrating a mean (SD) difference of 16 (23) ng/L. Total imprecision (CV) near the 100 ng/L cutoff was Ͻ12% for both assays.
In 2001, most BNP tests were requested by the emergency department (44%) and cardiology units (41%), noncardiac intensive care unit (ICU; 3.6%), general medicine (3.5%), and miscellaneous clinics (4.1%) (1 ) . In 2005, the emergency department ordered 41% and the cardiology units only 10%, diluted by the increase in test utilization by noncardiac ICUs (16%), general medicine units (15%), miscellaneous clinics (13%), cardiology clinics (3.5%), and miscellaneous inpatient services (1.2%; Table 1 ). Thirty percent of patients had a diagnosis of heart failure, and 70% did not. One half (50%) of the group were female. The mean (SD) ages of the heart failure and non-heart failure groups were 63 (15) and 58 (16) years, respectively (P Ͻ0.01). The median (interquartile range) BNP concentration was significantly greater for heart failure patients than for non-heart failure patients [482 (13-1024) ng/L vs 61 (5-161) ng/L, respectively; P Ͻ0.01]. BNP was increased (Ն100 ng/L) in 92.8% of patients with a diagnosis of heart failure and was within reference values in 53.6% of those without heart failure. In patients without a diagnosis of heart failure, 272 BNP tests had values Ն100 ng/L, representing 28% of ordered tests in these patients (without heart failure). Many of these patients had renal, other cardiovascular, pulmonary, or liver disease and/or multisystem pathology, which can also increase BNP. In patients with a diagnosis of heart failure, 28 BNP results were Ͻ100 ng/L. Possible explanations include confounding variables such as 
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vasodilator administration, acute dehydration, and/or intravenous diuresis. In addition, age-and sex-specific reference cutoffs were not used. A variety of in-and outpatient services now use BNP to assist in decision-making (Table 1) . When the diagnostic accuracy of BNP testing in a large prospective trial was first reported in 2002, the overall test sensitivity and specificity were 90% and 76%, respectively (2 ) . Similarly, we reported an apparent sensitivity and specificity of 94.8% and 77.1%, respectively (1 ). In the present report, BNP was increased in 92.8% of patients with a diagnosis of heart failure, suggesting that the sensitivity of the test remains high, but BNP was also high in Ͼ28% of patients who did not carry a heart failure diagnosis, suggesting that test specificity was much lower than 76%-77%. Although BNP was Ն100 ng/L in most patients with heart failure regardless of ordering location, it was also Ն100 ng/L in many patients without diagnosed heart failure, and this rate varied among locations (Table 1) . Most astounding was the noncardiac ICU, where the test was positive in Ͼ90% of patients without a discharge diagnosis of heart failure. Many of the patients in the ICU had acute and/or chronic renal failure, volume overload, and/or multisystem organ failure, which increased BNP test results in the absence of CHF. Many BNP tests were ordered on ICU patients whose admission notes indicated a history of renal failure.
Our previous study examined test utilization during a familiarization period, when a majority of physicians ordering tests likely had formal interactions with laboratory medicine and/or cardiology staff to guide appropriate use and interpretation of the newly implemented test (1 ). In the current study period, fewer physicians ordering tests had formal opportunities to review test utilization criteria. Thus, we suggest that physician education is an important component for maintaining test accuracy and appropriate use. Given that our hospital trains resident physicians, leading to a high annual provider turnover, we propose periodic utilization reviews and refresher training for BNP and other tests. These measures could serve to maximize test accuracy, mitigate test overuse, enhance physician education, and improve patient care.
Pediatric Tube Direct Sampling by the Abbott Architect Integrated ci8200 Chemistry/Immunochemistry Analyzer
To the Editor: Handling and direct sampling from primary, barcode-labeled pediatric tubes is a challenge for laboratories processing substantial numbers of pediatric samples (1, 2 ) . To prevent anemia as a result of frequent blood draws in pediatric patients, analyzers should be able to handle small sample volumes collected in pediatric tubes. However, most analyzers are developed for standard adult tubes and cannot handle primary pediatric tubes (1, 3 ) . Pediatric samples therefore are often manually processed and transferred to sample 
